Aclaris Therapeutics (ACRS) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Aclaris Therapeutics

NasdaqGS•Healthcare•Biotechnology

$5.45+0.13(0.02%)Market open

Market Cap

$785.05M

P/S

95.5x

P/B

6.3x

Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions. Aclaris Therapeutics, Inc. was incorporated in 2012 and is headquartered in Wayne, Pennsylvania.

How this company scores

WeakMetricSide Score: 36/100

Strongest: Balance Sheet & Red Flags (15/25); weakest: Growth (6/25).

Profitability8/25

Growth6/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality7/25

Strengths

Interest easily coveredProfit converts from growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 95.5x5y range 2.4x – 168.3x

Currently above its 20-quarter median.

P/B · 6.3x5y range 0.5x – 6.3x

Currently above its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 7 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $785.05M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $8.22M
Q. Revenue: $1.63M
TTM EBITDA: $-85.88M
TTM Op. Income: $-86.31M
Q. Op. Income: $-24.24M
TTM Net Income: $-75.74M
Q. Net Income: $-21.50M
EPS: $-0.15
Shares Out.: $142.74M

$8.22M in TTM revenue declined 51.0% YoY, reaching $1.63M last quarter. TTM EBITDA of $-85.88M and TTM operating income of $-86.31M show growth is flowing through to the bottom line. However, net income is negative at $75.74M — growth is not yet reaching the bottom line. Over the past year, TTM revenue is down 51% — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

EBITDA Margin: -1481.3%
Op. Margin: -1487.9%
Net Margin: -1320.1%

Op. margin of -1487.9% is down 452.0% YoY — costs are rising relative to revenue. Net margin at -1320.1% Over the past year, operating margin is down 44% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 95.5x
P/B Ratio: 6.3x

P/S of 95.5x and P/B of 6.3x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $179.69M
Cash: $19.17M
Long-Term Debt: N/A
Book Value: $124.58M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-19.85M
TTM Free Cash Flow: $-62.18M
FCF Margin: -756.5%
FCF / Net Income: 0.8

TTM FCF of $-62.18M on $-19.85M in operating cash flow. The FCF / Net Income ratio of 0.8x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 4 consecutive quarters — a weakening trend.